The Roles of Aerobic Exercise and Folate Supplementation in Hyperhomocysteinemia-Accelerated Atherosclerosis.
Aerobic exercise
Atherosclerosis
Folate
Homocysteine
Hyperhomocysteinemia
Journal
Acta Cardiologica Sinica
ISSN: 1011-6842
Titre abrégé: Acta Cardiol Sin
Pays: China (Republic : 1949- )
ID NLM: 101687085
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
20
04
2022
accepted:
27
10
2022
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
ppublish
Résumé
Hyperhomocysteinemia (HHcy) is an independent risk factor for atherosclerosis. Effective interventions to reduce HHcy-accelerated atherosclerosis are required. This study aimed to investigate the effects of aerobic exercise (AE) and folate (FA) supplementation on plasma homocysteine (Hcy) level and atherosclerosis development in a mouse model. Six-week-old female apoE-/- mice were grouped into five groups (N = 6-8): HHcy (1.8 g/L DL-homocysteine (DL-Hcy) in drinking water), HHcy + AE (1.8 g/L DL-Hcy and aerobic exercise training on a treadmill), HHcy + FA (1.8 g/L DL-Hcy and 0.006% folate in diet), HHcy + AE + FA (1.8 g/L DL-Hcy, 0.006% folate, and aerobic exercise training on a treadmill), and a control group (regular water and diet). All treatment was sustained for 8 weeks. Triglyceride, cholesterol, lipoprotein, and Hcy levels were determined enzymatically. Plaque and monocyte chemoattractant protein-1 (MCP-1) expression levels in mouse aortic roots were evaluated by immunohistochemistry. Compared to the HHcy group (18.88 ± 6.13 μmol/L), plasma Hcy concentration was significantly reduced in the HHcy + AE (14.79 ± 3.05 μmol/L, AE reduced atherosclerosis development in HHcy apoE-/- mice independently of reducing Hcy levels. FA supplementation decreased plasma Hcy levels without attenuating HHcy-accelerated atherosclerosis. AE and FA supplementation have distinct mechanisms in benefiting atherosclerosis.
Sections du résumé
Background
UNASSIGNED
Hyperhomocysteinemia (HHcy) is an independent risk factor for atherosclerosis. Effective interventions to reduce HHcy-accelerated atherosclerosis are required.
Objectives
UNASSIGNED
This study aimed to investigate the effects of aerobic exercise (AE) and folate (FA) supplementation on plasma homocysteine (Hcy) level and atherosclerosis development in a mouse model.
Methods
UNASSIGNED
Six-week-old female apoE-/- mice were grouped into five groups (N = 6-8): HHcy (1.8 g/L DL-homocysteine (DL-Hcy) in drinking water), HHcy + AE (1.8 g/L DL-Hcy and aerobic exercise training on a treadmill), HHcy + FA (1.8 g/L DL-Hcy and 0.006% folate in diet), HHcy + AE + FA (1.8 g/L DL-Hcy, 0.006% folate, and aerobic exercise training on a treadmill), and a control group (regular water and diet). All treatment was sustained for 8 weeks. Triglyceride, cholesterol, lipoprotein, and Hcy levels were determined enzymatically. Plaque and monocyte chemoattractant protein-1 (MCP-1) expression levels in mouse aortic roots were evaluated by immunohistochemistry.
Results
UNASSIGNED
Compared to the HHcy group (18.88 ± 6.13 μmol/L), plasma Hcy concentration was significantly reduced in the HHcy + AE (14.79 ± 3.05 μmol/L,
Conclusions
UNASSIGNED
AE reduced atherosclerosis development in HHcy apoE-/- mice independently of reducing Hcy levels. FA supplementation decreased plasma Hcy levels without attenuating HHcy-accelerated atherosclerosis. AE and FA supplementation have distinct mechanisms in benefiting atherosclerosis.
Identifiants
pubmed: 36911543
doi: 10.6515/ACS.202303_39(2).20221027A
pmc: PMC9999187
doi:
Types de publication
Journal Article
Langues
eng
Pagination
309-318Références
Can J Physiol Pharmacol. 2014 Jul;92(7):575-82
pubmed: 24923386
Circ Res. 2003 Aug 22;93(4):311-20
pubmed: 12881478
Int J Mol Sci. 2022 Mar 30;23(7):
pubmed: 35409148
Front Cardiovasc Med. 2021 Sep 06;8:707529
pubmed: 34552965
Circulation. 2020 Apr 21;141(16):1338-1350
pubmed: 32310695
Front Immunol. 2016 Jul 26;7:285
pubmed: 27507972
Cureus. 2020 Nov 23;12(11):e11641
pubmed: 33376653
Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1361-8
pubmed: 19666835
Ann Afr Med. 2019 Jul-Sep;18(3):143-152
pubmed: 31417015
FEBS Lett. 2009 Apr 17;583(8):1215-25
pubmed: 19324042
Nutr J. 2015 Jan 10;14:6
pubmed: 25577237
Atherosclerosis. 2008 Apr;197(2):620-9
pubmed: 17950295
Braz J Med Biol Res. 2010 Jan;43(1):1-7
pubmed: 19967264
Int J Mol Sci. 2017 May 05;18(5):
pubmed: 28475147
J Vis Exp. 2019 Jun 12;(148):
pubmed: 31259915
Int J Clin Exp Pathol. 2015 Oct 01;8(10):12829-36
pubmed: 26722473
Ann N Y Acad Sci. 2016 Jan;1363:138-54
pubmed: 26849408
Redox Biol. 2018 Apr;14:116-125
pubmed: 28888894
Physiol Rep. 2018 Mar;6(6):e13637
pubmed: 29595876
Nutr Metab (Lond). 2017 Nov 02;14:68
pubmed: 29118818
Nutr Res. 2013 Jun;33(6):487-93
pubmed: 23746565
Afr Health Sci. 2019 Dec;19(4):2874-2880
pubmed: 32127863
Front Cardiovasc Med. 2019 Apr 12;6:46
pubmed: 31032262
Postgrad Med. 2020 Jun;132(5):458-464
pubmed: 32167398
Int J Mol Sci. 2017 Sep 22;18(10):
pubmed: 28937652
Obes Res Clin Pract. 2020 May - Jun;14(3):264-270
pubmed: 32444302
Curr Pharm Des. 2014;20(28):4580-8
pubmed: 24862889
Nutrients. 2021 Aug 30;13(9):
pubmed: 34578910
Front Physiol. 2021 Nov 29;12:774681
pubmed: 34912240
PLoS One. 2012;7(12):e51185
pubmed: 23236449
Acta Cardiol Sin. 2020 May;36(3):260-267
pubmed: 32425441
PLoS One. 2016 Mar 17;11(3):e0151653
pubmed: 26986570
Cardiovasc Pathol. 2007 Sep-Oct;16(5):305-9
pubmed: 17868882
Int J Prev Med. 2014 Aug;5(8):1060-6
pubmed: 25489457
Sci Rep. 2019 Apr 4;9(1):5612
pubmed: 30948751
BMC Cardiovasc Disord. 2020 Feb 3;20(1):44
pubmed: 32013876
Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1596-605
pubmed: 18556571
Int J Mol Sci. 2015 Jun 03;16(6):12560-77
pubmed: 26047341
Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1470-6
pubmed: 11557674
Lipids Health Dis. 2017 Jul 5;16(1):132
pubmed: 28679436
Int J Epidemiol. 2019 Oct 1;48(5):1389-1392
pubmed: 30968109
Circulation. 2004 Jul 13;110(2):207-13
pubmed: 15210586
Nature. 2000 Sep 14;407(6801):233-41
pubmed: 11001066
Curr Med Chem. 2019;26(16):2948-2961
pubmed: 29532755
Am J Physiol Heart Circ Physiol. 2010 Nov;299(5):H1484-93
pubmed: 20802128
Nutr Res. 2018 May;53:40-50
pubmed: 29685624
Eur Rev Med Pharmacol Sci. 2016 Sep;20(18):3863-3867
pubmed: 27735029
Eur J Appl Physiol. 2006 May;97(2):216-24
pubmed: 16583233
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Acta Cardiol Sin. 2018 Nov;34(6):458-463
pubmed: 30449985
PLoS One. 2015 Mar 18;10(3):e0120633
pubmed: 25786118
Medicine (Baltimore). 2021 Mar 19;100(11):e24846
pubmed: 33725956
BMC Cardiovasc Disord. 2017 Jan 21;17(1):37
pubmed: 28109191
J Am Coll Nutr. 2017 Sep-Oct;36(7):528-532
pubmed: 28854002
Oxid Med Cell Longev. 2020 Sep 15;2020:5245308
pubmed: 33014272
Am J Clin Nutr. 2001 Apr;73(4):759-64
pubmed: 11273851
Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1100-H1138
pubmed: 32196357
Indian J Exp Biol. 2008 Jul;46(7):534-40
pubmed: 18807758
Expert Rev Cardiovasc Ther. 2018 Aug;16(8):559-565
pubmed: 29979619
Dig Dis Sci. 2018 Dec;63(12):3161-3163
pubmed: 30191498
Reprod Sci. 2022 Jan;29(1):277-290
pubmed: 34494235
Biomedicines. 2020 Jun 18;8(6):
pubmed: 32570831